Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Go back to Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure| Amgen Inc (NASDAQ: AMGN) | Delayed: 394.54 -42.69 (9.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $437.23 | 52 Week High | $176.85 | |||
| Open | $408.90 | 52 Week Low | $133.64 | |||
| Day High | $410.03 | P/E | 59.42 | |||
| Day Low | $392.00 | EPS | $6.64 | |||
| Volume | 2,947,834 | |||||
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 75.80 +3.08 (4.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $72.72 | 52 Week High | $13.18 | |||
| Open | $72.39 | 52 Week Low | $6.00 | |||
| Day High | $76.81 | P/E | N/A | |||
| Day Low | $72.39 | EPS | $-1.24 | |||
| Volume | 1,034,605 | |||||
